nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—SLC22A2—Progesterone—uterine cancer	0.144	0.177	CbGbCtD
Propranolol—CYP1A1—Progesterone—uterine cancer	0.0981	0.12	CbGbCtD
Propranolol—CYP3A7—Progesterone—uterine cancer	0.0785	0.0963	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0785	0.0963	CbGbCtD
Propranolol—CYP3A5—Progesterone—uterine cancer	0.0589	0.0723	CbGbCtD
Propranolol—CYP2C19—Progesterone—uterine cancer	0.0475	0.0583	CbGbCtD
Propranolol—CYP1A2—Progesterone—uterine cancer	0.0438	0.0538	CbGbCtD
Propranolol—ABCB1—Progesterone—uterine cancer	0.0383	0.047	CbGbCtD
Propranolol—CYP2D6—Progesterone—uterine cancer	0.0361	0.0443	CbGbCtD
Propranolol—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0347	0.0425	CbGbCtD
Propranolol—ABCB1—Dactinomycin—uterine cancer	0.0304	0.0373	CbGbCtD
Propranolol—CYP3A5—Etoposide—uterine cancer	0.0263	0.0323	CbGbCtD
Propranolol—CYP3A4—Progesterone—uterine cancer	0.023	0.0282	CbGbCtD
Propranolol—CYP1A2—Etoposide—uterine cancer	0.0196	0.0241	CbGbCtD
Propranolol—ABCB1—Etoposide—uterine cancer	0.0171	0.021	CbGbCtD
Propranolol—ABCB1—Doxorubicin—uterine cancer	0.0117	0.0144	CbGbCtD
Propranolol—CYP2D6—Doxorubicin—uterine cancer	0.011	0.0135	CbGbCtD
Propranolol—CYP3A4—Etoposide—uterine cancer	0.0103	0.0126	CbGbCtD
Propranolol—CYP3A4—Doxorubicin—uterine cancer	0.00701	0.0086	CbGbCtD
Propranolol—Terbinafine—CYP11A1—uterine cancer	0.00234	0.525	CrCbGaD
Propranolol—HTR1B—artery—uterine cancer	0.00139	0.11	CbGeAlD
Propranolol—Terbinafine—CYP19A1—uterine cancer	0.00121	0.271	CrCbGaD
Propranolol—Carvedilol—VEGFA—uterine cancer	0.000909	0.204	CrCbGaD
Propranolol—ADRB3—female reproductive system—uterine cancer	0.000898	0.0714	CbGeAlD
Propranolol—Visual impairment—Medroxyprogesterone Acetate—uterine cancer	0.000832	0.00528	CcSEcCtD
Propranolol—Erythema—Progesterone—uterine cancer	0.00083	0.00526	CcSEcCtD
Propranolol—ADRB3—female gonad—uterine cancer	0.000817	0.065	CbGeAlD
Propranolol—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.000817	0.00518	CcSEcCtD
Propranolol—Cardiac disorder—Medroxyprogesterone Acetate—uterine cancer	0.000802	0.00508	CcSEcCtD
Propranolol—Neutropenia—Dactinomycin—uterine cancer	0.000787	0.00499	CcSEcCtD
Propranolol—Cardiac failure congestive—Etoposide—uterine cancer	0.000777	0.00493	CcSEcCtD
Propranolol—Alopecia—Medroxyprogesterone Acetate—uterine cancer	0.000763	0.00484	CcSEcCtD
Propranolol—Mental disorder—Medroxyprogesterone Acetate—uterine cancer	0.000757	0.0048	CcSEcCtD
Propranolol—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.000752	0.00477	CcSEcCtD
Propranolol—Vertigo—Progesterone—uterine cancer	0.000746	0.00473	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.000744	0.00472	CcSEcCtD
Propranolol—Anaphylactoid reaction—Etoposide—uterine cancer	0.000728	0.00462	CcSEcCtD
Propranolol—Cough—Progesterone—uterine cancer	0.000724	0.00459	CcSEcCtD
Propranolol—Convulsion—Progesterone—uterine cancer	0.000719	0.00456	CcSEcCtD
Propranolol—Rash erythematous—Epirubicin—uterine cancer	0.000711	0.00451	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000702	0.00445	CcSEcCtD
Propranolol—Agranulocytosis—Dactinomycin—uterine cancer	0.0007	0.00444	CcSEcCtD
Propranolol—Skin ulcer—Epirubicin—uterine cancer	0.000699	0.00443	CcSEcCtD
Propranolol—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.000691	0.00438	CcSEcCtD
Propranolol—Anaphylactic shock—Progesterone—uterine cancer	0.000677	0.00429	CcSEcCtD
Propranolol—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.000676	0.00428	CcSEcCtD
Propranolol—SLC22A2—renal system—uterine cancer	0.000674	0.0536	CbGeAlD
Propranolol—Infection—Progesterone—uterine cancer	0.000673	0.00427	CcSEcCtD
Propranolol—Cardiac arrest—Etoposide—uterine cancer	0.00067	0.00425	CcSEcCtD
Propranolol—Pharyngitis—Dactinomycin—uterine cancer	0.000669	0.00424	CcSEcCtD
Propranolol—Nervous system disorder—Progesterone—uterine cancer	0.000664	0.00421	CcSEcCtD
Propranolol—Skin disorder—Progesterone—uterine cancer	0.000658	0.00417	CcSEcCtD
Propranolol—Rash erythematous—Doxorubicin—uterine cancer	0.000658	0.00417	CcSEcCtD
Propranolol—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.000651	0.00413	CcSEcCtD
Propranolol—Skin ulcer—Doxorubicin—uterine cancer	0.000647	0.0041	CcSEcCtD
Propranolol—Erythema multiforme—Dactinomycin—uterine cancer	0.000637	0.00404	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000636	0.00403	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Etoposide—uterine cancer	0.000635	0.00403	CcSEcCtD
Propranolol—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.000614	0.00389	CcSEcCtD
Propranolol—Insomnia—Progesterone—uterine cancer	0.000613	0.00388	CcSEcCtD
Propranolol—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00061	0.00387	CcSEcCtD
Propranolol—Paraesthesia—Progesterone—uterine cancer	0.000608	0.00386	CcSEcCtD
Propranolol—Dyspnoea—Progesterone—uterine cancer	0.000604	0.00383	CcSEcCtD
Propranolol—Somnolence—Progesterone—uterine cancer	0.000602	0.00382	CcSEcCtD
Propranolol—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000602	0.00382	CcSEcCtD
Propranolol—Bronchospasm—Etoposide—uterine cancer	0.000599	0.0038	CcSEcCtD
Propranolol—Dyspepsia—Progesterone—uterine cancer	0.000596	0.00378	CcSEcCtD
Propranolol—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000596	0.00378	CcSEcCtD
Propranolol—Alopecia—Dactinomycin—uterine cancer	0.000595	0.00378	CcSEcCtD
Propranolol—Decreased appetite—Progesterone—uterine cancer	0.000589	0.00373	CcSEcCtD
Propranolol—Erythema—Dactinomycin—uterine cancer	0.000586	0.00372	CcSEcCtD
Propranolol—Gastrointestinal disorder—Progesterone—uterine cancer	0.000585	0.00371	CcSEcCtD
Propranolol—Fatigue—Progesterone—uterine cancer	0.000584	0.0037	CcSEcCtD
Propranolol—Pain—Progesterone—uterine cancer	0.000579	0.00367	CcSEcCtD
Propranolol—Constipation—Progesterone—uterine cancer	0.000579	0.00367	CcSEcCtD
Propranolol—Neutropenia—Etoposide—uterine cancer	0.00057	0.00361	CcSEcCtD
Propranolol—Atrioventricular block—Epirubicin—uterine cancer	0.000561	0.00356	CcSEcCtD
Propranolol—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000555	0.00352	CcSEcCtD
Propranolol—Gastrointestinal pain—Progesterone—uterine cancer	0.000554	0.00351	CcSEcCtD
Propranolol—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000551	0.00349	CcSEcCtD
Propranolol—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000547	0.00347	CcSEcCtD
Propranolol—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000546	0.00346	CcSEcCtD
Propranolol—Infestation NOS—Etoposide—uterine cancer	0.000543	0.00344	CcSEcCtD
Propranolol—Infestation—Etoposide—uterine cancer	0.000543	0.00344	CcSEcCtD
Propranolol—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00054	0.00343	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000539	0.00342	CcSEcCtD
Propranolol—Urticaria—Progesterone—uterine cancer	0.000538	0.00341	CcSEcCtD
Propranolol—Abnormal dreams—Epirubicin—uterine cancer	0.000538	0.00341	CcSEcCtD
Propranolol—Abdominal pain—Progesterone—uterine cancer	0.000535	0.0034	CcSEcCtD
Propranolol—Body temperature increased—Progesterone—uterine cancer	0.000535	0.0034	CcSEcCtD
Propranolol—Hyperkalaemia—Epirubicin—uterine cancer	0.000535	0.00339	CcSEcCtD
Propranolol—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000533	0.00338	CcSEcCtD
Propranolol—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00053	0.00336	CcSEcCtD
Propranolol—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000529	0.00336	CcSEcCtD
Propranolol—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000525	0.00333	CcSEcCtD
Propranolol—Atrioventricular block—Doxorubicin—uterine cancer	0.000519	0.00329	CcSEcCtD
Propranolol—Agranulocytosis—Etoposide—uterine cancer	0.000507	0.00321	CcSEcCtD
Propranolol—Dry eye—Epirubicin—uterine cancer	0.000503	0.00319	CcSEcCtD
Propranolol—ORM1—endometrium—uterine cancer	0.000503	0.04	CbGeAlD
Propranolol—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000502	0.00318	CcSEcCtD
Propranolol—Hypersensitivity—Progesterone—uterine cancer	0.000499	0.00316	CcSEcCtD
Propranolol—Abnormal dreams—Doxorubicin—uterine cancer	0.000498	0.00316	CcSEcCtD
Propranolol—Hyperkalaemia—Doxorubicin—uterine cancer	0.000495	0.00314	CcSEcCtD
Propranolol—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000488	0.00309	CcSEcCtD
Propranolol—Asthenia—Progesterone—uterine cancer	0.000486	0.00308	CcSEcCtD
Propranolol—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000485	0.00308	CcSEcCtD
Propranolol—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000485	0.00308	CcSEcCtD
Propranolol—Infection—Dactinomycin—uterine cancer	0.000476	0.00302	CcSEcCtD
Propranolol—Dry eye—Doxorubicin—uterine cancer	0.000465	0.00295	CcSEcCtD
Propranolol—Diarrhoea—Progesterone—uterine cancer	0.000463	0.00294	CcSEcCtD
Propranolol—Erythema multiforme—Etoposide—uterine cancer	0.000461	0.00292	CcSEcCtD
Propranolol—Cardiac disorder—Etoposide—uterine cancer	0.000453	0.00287	CcSEcCtD
Propranolol—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000452	0.00287	CcSEcCtD
Propranolol—Dizziness—Progesterone—uterine cancer	0.000448	0.00284	CcSEcCtD
Propranolol—Vascular purpura—Epirubicin—uterine cancer	0.000442	0.0028	CcSEcCtD
Propranolol—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00044	0.00279	CcSEcCtD
Propranolol—Cardiac failure congestive—Epirubicin—uterine cancer	0.000436	0.00276	CcSEcCtD
Propranolol—Alopecia—Etoposide—uterine cancer	0.000431	0.00273	CcSEcCtD
Propranolol—Vomiting—Progesterone—uterine cancer	0.000431	0.00273	CcSEcCtD
Propranolol—Rash—Progesterone—uterine cancer	0.000427	0.00271	CcSEcCtD
Propranolol—Dermatitis—Progesterone—uterine cancer	0.000427	0.00271	CcSEcCtD
Propranolol—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00042	0.00266	CcSEcCtD
Propranolol—Dermatitis exfoliative—Epirubicin—uterine cancer	0.000419	0.00266	CcSEcCtD
Propranolol—ORM1—female reproductive system—uterine cancer	0.000416	0.0331	CbGeAlD
Propranolol—Decreased appetite—Dactinomycin—uterine cancer	0.000416	0.00264	CcSEcCtD
Propranolol—Fatigue—Dactinomycin—uterine cancer	0.000413	0.00262	CcSEcCtD
Propranolol—Purpura—Epirubicin—uterine cancer	0.00041	0.0026	CcSEcCtD
Propranolol—Pain—Dactinomycin—uterine cancer	0.000409	0.0026	CcSEcCtD
Propranolol—Vascular purpura—Doxorubicin—uterine cancer	0.000409	0.00259	CcSEcCtD
Propranolol—Anaphylactoid reaction—Epirubicin—uterine cancer	0.000408	0.00259	CcSEcCtD
Propranolol—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000406	0.00257	CcSEcCtD
Propranolol—Hypoglycaemia—Epirubicin—uterine cancer	0.000405	0.00257	CcSEcCtD
Propranolol—Lethargy—Epirubicin—uterine cancer	0.000403	0.00256	CcSEcCtD
Propranolol—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000403	0.00256	CcSEcCtD
Propranolol—Nausea—Progesterone—uterine cancer	0.000402	0.00255	CcSEcCtD
Propranolol—HTR1A—renal system—uterine cancer	0.000393	0.0313	CbGeAlD
Propranolol—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000391	0.00248	CcSEcCtD
Propranolol—HTR1B—female reproductive system—uterine cancer	0.00039	0.031	CbGeAlD
Propranolol—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00039	0.00247	CcSEcCtD
Propranolol—Affect lability—Epirubicin—uterine cancer	0.000389	0.00247	CcSEcCtD
Propranolol—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.000387	0.00246	CcSEcCtD
Propranolol—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000387	0.00245	CcSEcCtD
Propranolol—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000387	0.00245	CcSEcCtD
Propranolol—Vertigo—Etoposide—uterine cancer	0.000381	0.00242	CcSEcCtD
Propranolol—Purpura—Doxorubicin—uterine cancer	0.000379	0.00241	CcSEcCtD
Propranolol—Body temperature increased—Dactinomycin—uterine cancer	0.000378	0.0024	CcSEcCtD
Propranolol—Abdominal pain—Dactinomycin—uterine cancer	0.000378	0.0024	CcSEcCtD
Propranolol—Anaphylactoid reaction—Doxorubicin—uterine cancer	0.000378	0.0024	CcSEcCtD
Propranolol—Cardiac arrest—Epirubicin—uterine cancer	0.000376	0.00238	CcSEcCtD
Propranolol—Hypoglycaemia—Doxorubicin—uterine cancer	0.000375	0.00238	CcSEcCtD
Propranolol—Mood swings—Epirubicin—uterine cancer	0.000374	0.00237	CcSEcCtD
Propranolol—Lethargy—Doxorubicin—uterine cancer	0.000373	0.00237	CcSEcCtD
Propranolol—Cough—Etoposide—uterine cancer	0.00037	0.00235	CcSEcCtD
Propranolol—Convulsion—Etoposide—uterine cancer	0.000368	0.00233	CcSEcCtD
Propranolol—ADRB1—female reproductive system—uterine cancer	0.000367	0.0292	CbGeAlD
Propranolol—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000365	0.00231	CcSEcCtD
Propranolol—Affect lability—Doxorubicin—uterine cancer	0.00036	0.00228	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000359	0.00228	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000356	0.00226	CcSEcCtD
Propranolol—Hypersensitivity—Dactinomycin—uterine cancer	0.000353	0.00224	CcSEcCtD
Propranolol—Cardiac arrest—Doxorubicin—uterine cancer	0.000348	0.0022	CcSEcCtD
Propranolol—Anaphylactic shock—Etoposide—uterine cancer	0.000346	0.0022	CcSEcCtD
Propranolol—Mood swings—Doxorubicin—uterine cancer	0.000346	0.0022	CcSEcCtD
Propranolol—Infection—Etoposide—uterine cancer	0.000344	0.00218	CcSEcCtD
Propranolol—Asthenia—Dactinomycin—uterine cancer	0.000343	0.00218	CcSEcCtD
Propranolol—Skin disorder—Etoposide—uterine cancer	0.000336	0.00213	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000329	0.00209	CcSEcCtD
Propranolol—Bronchitis—Epirubicin—uterine cancer	0.000328	0.00208	CcSEcCtD
Propranolol—Diarrhoea—Dactinomycin—uterine cancer	0.000328	0.00208	CcSEcCtD
Propranolol—Neutropenia—Epirubicin—uterine cancer	0.000319	0.00203	CcSEcCtD
Propranolol—CYP1A1—epithelium—uterine cancer	0.000319	0.0254	CbGeAlD
Propranolol—CYP1A1—uterine cervix—uterine cancer	0.000316	0.0251	CbGeAlD
Propranolol—Paraesthesia—Etoposide—uterine cancer	0.000311	0.00197	CcSEcCtD
Propranolol—CYP3A5—uterine cervix—uterine cancer	0.000309	0.0246	CbGeAlD
Propranolol—Dyspnoea—Etoposide—uterine cancer	0.000309	0.00196	CcSEcCtD
Propranolol—Somnolence—Etoposide—uterine cancer	0.000308	0.00195	CcSEcCtD
Propranolol—Infestation—Epirubicin—uterine cancer	0.000304	0.00193	CcSEcCtD
Propranolol—Infestation NOS—Epirubicin—uterine cancer	0.000304	0.00193	CcSEcCtD
Propranolol—Vomiting—Dactinomycin—uterine cancer	0.000304	0.00193	CcSEcCtD
Propranolol—Bronchitis—Doxorubicin—uterine cancer	0.000304	0.00193	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000302	0.00191	CcSEcCtD
Propranolol—Rash—Dactinomycin—uterine cancer	0.000302	0.00191	CcSEcCtD
Propranolol—Decreased appetite—Etoposide—uterine cancer	0.000301	0.00191	CcSEcCtD
Propranolol—CYP1A2—renal system—uterine cancer	0.0003	0.0238	CbGeAlD
Propranolol—Gastrointestinal disorder—Etoposide—uterine cancer	0.000299	0.0019	CcSEcCtD
Propranolol—Fatigue—Etoposide—uterine cancer	0.000299	0.00189	CcSEcCtD
Propranolol—Constipation—Etoposide—uterine cancer	0.000296	0.00188	CcSEcCtD
Propranolol—Pain—Etoposide—uterine cancer	0.000296	0.00188	CcSEcCtD
Propranolol—CYP1A1—renal system—uterine cancer	0.000296	0.0235	CbGeAlD
Propranolol—Neutropenia—Doxorubicin—uterine cancer	0.000295	0.00187	CcSEcCtD
Propranolol—CYP3A5—renal system—uterine cancer	0.000289	0.023	CbGeAlD
Propranolol—Nausea—Dactinomycin—uterine cancer	0.000284	0.0018	CcSEcCtD
Propranolol—Agranulocytosis—Epirubicin—uterine cancer	0.000284	0.0018	CcSEcCtD
Propranolol—Gastrointestinal pain—Etoposide—uterine cancer	0.000283	0.0018	CcSEcCtD
Propranolol—Infestation—Doxorubicin—uterine cancer	0.000282	0.00179	CcSEcCtD
Propranolol—Infestation NOS—Doxorubicin—uterine cancer	0.000282	0.00179	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000279	0.00177	CcSEcCtD
Propranolol—Bradycardia—Epirubicin—uterine cancer	0.000278	0.00176	CcSEcCtD
Propranolol—CYP1A1—mammalian vulva—uterine cancer	0.000277	0.022	CbGeAlD
Propranolol—Urticaria—Etoposide—uterine cancer	0.000275	0.00175	CcSEcCtD
Propranolol—Body temperature increased—Etoposide—uterine cancer	0.000274	0.00174	CcSEcCtD
Propranolol—Abdominal pain—Etoposide—uterine cancer	0.000274	0.00174	CcSEcCtD
Propranolol—Pharyngitis—Epirubicin—uterine cancer	0.000271	0.00172	CcSEcCtD
Propranolol—CYP2C19—vagina—uterine cancer	0.000266	0.0211	CbGeAlD
Propranolol—CYP1A1—uterus—uterine cancer	0.000263	0.0209	CbGeAlD
Propranolol—Visual impairment—Epirubicin—uterine cancer	0.000263	0.00167	CcSEcCtD
Propranolol—Agranulocytosis—Doxorubicin—uterine cancer	0.000263	0.00167	CcSEcCtD
Propranolol—Erythema multiforme—Epirubicin—uterine cancer	0.000258	0.00164	CcSEcCtD
Propranolol—Bradycardia—Doxorubicin—uterine cancer	0.000257	0.00163	CcSEcCtD
Propranolol—Hypersensitivity—Etoposide—uterine cancer	0.000255	0.00162	CcSEcCtD
Propranolol—Cardiac disorder—Epirubicin—uterine cancer	0.000254	0.00161	CcSEcCtD
Propranolol—Pharyngitis—Doxorubicin—uterine cancer	0.000251	0.00159	CcSEcCtD
Propranolol—Asthenia—Etoposide—uterine cancer	0.000249	0.00158	CcSEcCtD
Propranolol—Visual impairment—Doxorubicin—uterine cancer	0.000244	0.00155	CcSEcCtD
Propranolol—ORM1—lymph node—uterine cancer	0.000244	0.0194	CbGeAlD
Propranolol—Alopecia—Epirubicin—uterine cancer	0.000242	0.00153	CcSEcCtD
Propranolol—Mental disorder—Epirubicin—uterine cancer	0.000239	0.00152	CcSEcCtD
Propranolol—Erythema multiforme—Doxorubicin—uterine cancer	0.000239	0.00152	CcSEcCtD
Propranolol—Erythema—Epirubicin—uterine cancer	0.000238	0.00151	CcSEcCtD
Propranolol—Diarrhoea—Etoposide—uterine cancer	0.000237	0.0015	CcSEcCtD
Propranolol—CYP1A1—female reproductive system—uterine cancer	0.000237	0.0188	CbGeAlD
Propranolol—Cardiac disorder—Doxorubicin—uterine cancer	0.000235	0.00149	CcSEcCtD
Propranolol—Dizziness—Etoposide—uterine cancer	0.000229	0.00145	CcSEcCtD
Propranolol—Alopecia—Doxorubicin—uterine cancer	0.000223	0.00142	CcSEcCtD
Propranolol—Mental disorder—Doxorubicin—uterine cancer	0.000222	0.00141	CcSEcCtD
Propranolol—Vomiting—Etoposide—uterine cancer	0.00022	0.0014	CcSEcCtD
Propranolol—Erythema—Doxorubicin—uterine cancer	0.00022	0.0014	CcSEcCtD
Propranolol—Agitation—Epirubicin—uterine cancer	0.000219	0.00139	CcSEcCtD
Propranolol—Rash—Etoposide—uterine cancer	0.000218	0.00139	CcSEcCtD
Propranolol—Dermatitis—Etoposide—uterine cancer	0.000218	0.00138	CcSEcCtD
Propranolol—CYP3A4—renal system—uterine cancer	0.000217	0.0173	CbGeAlD
Propranolol—CYP1A1—female gonad—uterine cancer	0.000215	0.0171	CbGeAlD
Propranolol—CYP1A1—vagina—uterine cancer	0.000214	0.017	CbGeAlD
Propranolol—Vertigo—Epirubicin—uterine cancer	0.000214	0.00136	CcSEcCtD
Propranolol—CYP2D6—renal system—uterine cancer	0.000214	0.017	CbGeAlD
Propranolol—ABCB1—myometrium—uterine cancer	0.000211	0.0168	CbGeAlD
Propranolol—CYP3A5—female gonad—uterine cancer	0.000211	0.0168	CbGeAlD
Propranolol—CYP3A5—vagina—uterine cancer	0.000209	0.0167	CbGeAlD
Propranolol—Cough—Epirubicin—uterine cancer	0.000208	0.00132	CcSEcCtD
Propranolol—Convulsion—Epirubicin—uterine cancer	0.000206	0.00131	CcSEcCtD
Propranolol—Nausea—Etoposide—uterine cancer	0.000206	0.0013	CcSEcCtD
Propranolol—Agitation—Doxorubicin—uterine cancer	0.000202	0.00128	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000201	0.00128	CcSEcCtD
Propranolol—Vertigo—Doxorubicin—uterine cancer	0.000198	0.00125	CcSEcCtD
Propranolol—Anaphylactic shock—Epirubicin—uterine cancer	0.000194	0.00123	CcSEcCtD
Propranolol—Infection—Epirubicin—uterine cancer	0.000193	0.00122	CcSEcCtD
Propranolol—Cough—Doxorubicin—uterine cancer	0.000192	0.00122	CcSEcCtD
Propranolol—Convulsion—Doxorubicin—uterine cancer	0.000191	0.00121	CcSEcCtD
Propranolol—Nervous system disorder—Epirubicin—uterine cancer	0.00019	0.00121	CcSEcCtD
Propranolol—Skin disorder—Epirubicin—uterine cancer	0.000189	0.0012	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000186	0.00118	CcSEcCtD
Propranolol—Anaphylactic shock—Doxorubicin—uterine cancer	0.00018	0.00114	CcSEcCtD
Propranolol—Infection—Doxorubicin—uterine cancer	0.000179	0.00113	CcSEcCtD
Propranolol—Nervous system disorder—Doxorubicin—uterine cancer	0.000176	0.00112	CcSEcCtD
Propranolol—Insomnia—Epirubicin—uterine cancer	0.000176	0.00111	CcSEcCtD
Propranolol—Skin disorder—Doxorubicin—uterine cancer	0.000175	0.00111	CcSEcCtD
Propranolol—Paraesthesia—Epirubicin—uterine cancer	0.000174	0.00111	CcSEcCtD
Propranolol—CYP3A4—female reproductive system—uterine cancer	0.000174	0.0138	CbGeAlD
Propranolol—Dyspnoea—Epirubicin—uterine cancer	0.000173	0.0011	CcSEcCtD
Propranolol—Somnolence—Epirubicin—uterine cancer	0.000173	0.00109	CcSEcCtD
Propranolol—CYP2D6—female reproductive system—uterine cancer	0.000171	0.0136	CbGeAlD
Propranolol—Dyspepsia—Epirubicin—uterine cancer	0.000171	0.00108	CcSEcCtD
Propranolol—Decreased appetite—Epirubicin—uterine cancer	0.000169	0.00107	CcSEcCtD
Propranolol—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000168	0.00106	CcSEcCtD
Propranolol—Fatigue—Epirubicin—uterine cancer	0.000167	0.00106	CcSEcCtD
Propranolol—Constipation—Epirubicin—uterine cancer	0.000166	0.00105	CcSEcCtD
Propranolol—Pain—Epirubicin—uterine cancer	0.000166	0.00105	CcSEcCtD
Propranolol—ABCB1—epithelium—uterine cancer	0.000166	0.0132	CbGeAlD
Propranolol—ABCB1—uterine cervix—uterine cancer	0.000164	0.0131	CbGeAlD
Propranolol—Insomnia—Doxorubicin—uterine cancer	0.000163	0.00103	CcSEcCtD
Propranolol—Paraesthesia—Doxorubicin—uterine cancer	0.000161	0.00102	CcSEcCtD
Propranolol—Dyspnoea—Doxorubicin—uterine cancer	0.00016	0.00102	CcSEcCtD
Propranolol—Somnolence—Doxorubicin—uterine cancer	0.00016	0.00101	CcSEcCtD
Propranolol—Gastrointestinal pain—Epirubicin—uterine cancer	0.000159	0.00101	CcSEcCtD
Propranolol—Dyspepsia—Doxorubicin—uterine cancer	0.000158	0.001	CcSEcCtD
Propranolol—ABCB1—decidua—uterine cancer	0.000156	0.0124	CbGeAlD
Propranolol—Decreased appetite—Doxorubicin—uterine cancer	0.000156	0.000991	CcSEcCtD
Propranolol—CYP2D6—female gonad—uterine cancer	0.000156	0.0124	CbGeAlD
Propranolol—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000155	0.000984	CcSEcCtD
Propranolol—Fatigue—Doxorubicin—uterine cancer	0.000155	0.000982	CcSEcCtD
Propranolol—Urticaria—Epirubicin—uterine cancer	0.000154	0.000978	CcSEcCtD
Propranolol—Constipation—Doxorubicin—uterine cancer	0.000154	0.000974	CcSEcCtD
Propranolol—Pain—Doxorubicin—uterine cancer	0.000154	0.000974	CcSEcCtD
Propranolol—ABCB1—renal system—uterine cancer	0.000154	0.0122	CbGeAlD
Propranolol—Abdominal pain—Epirubicin—uterine cancer	0.000154	0.000974	CcSEcCtD
Propranolol—Body temperature increased—Epirubicin—uterine cancer	0.000154	0.000974	CcSEcCtD
Propranolol—ABCB1—endometrium—uterine cancer	0.000148	0.0118	CbGeAlD
Propranolol—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000147	0.000932	CcSEcCtD
Propranolol—ABCB1—mammalian vulva—uterine cancer	0.000144	0.0114	CbGeAlD
Propranolol—Hypersensitivity—Epirubicin—uterine cancer	0.000143	0.000907	CcSEcCtD
Propranolol—Urticaria—Doxorubicin—uterine cancer	0.000143	0.000905	CcSEcCtD
Propranolol—Body temperature increased—Doxorubicin—uterine cancer	0.000142	0.000901	CcSEcCtD
Propranolol—Abdominal pain—Doxorubicin—uterine cancer	0.000142	0.000901	CcSEcCtD
Propranolol—Asthenia—Epirubicin—uterine cancer	0.000139	0.000884	CcSEcCtD
Propranolol—CYP1A1—lymph node—uterine cancer	0.000139	0.011	CbGeAlD
Propranolol—ABCB1—uterus—uterine cancer	0.000137	0.0109	CbGeAlD
Propranolol—Diarrhoea—Epirubicin—uterine cancer	0.000133	0.000843	CcSEcCtD
Propranolol—Hypersensitivity—Doxorubicin—uterine cancer	0.000132	0.00084	CcSEcCtD
Propranolol—Asthenia—Doxorubicin—uterine cancer	0.000129	0.000818	CcSEcCtD
Propranolol—Dizziness—Epirubicin—uterine cancer	0.000128	0.000814	CcSEcCtD
Propranolol—Vomiting—Epirubicin—uterine cancer	0.000123	0.000783	CcSEcCtD
Propranolol—ABCB1—female reproductive system—uterine cancer	0.000123	0.00978	CbGeAlD
Propranolol—Diarrhoea—Doxorubicin—uterine cancer	0.000123	0.00078	CcSEcCtD
Propranolol—Rash—Epirubicin—uterine cancer	0.000122	0.000777	CcSEcCtD
Propranolol—Dermatitis—Epirubicin—uterine cancer	0.000122	0.000776	CcSEcCtD
Propranolol—Dizziness—Doxorubicin—uterine cancer	0.000119	0.000754	CcSEcCtD
Propranolol—Nausea—Epirubicin—uterine cancer	0.000115	0.000732	CcSEcCtD
Propranolol—Vomiting—Doxorubicin—uterine cancer	0.000114	0.000725	CcSEcCtD
Propranolol—Rash—Doxorubicin—uterine cancer	0.000113	0.000718	CcSEcCtD
Propranolol—Dermatitis—Doxorubicin—uterine cancer	0.000113	0.000718	CcSEcCtD
Propranolol—ABCB1—female gonad—uterine cancer	0.000112	0.0089	CbGeAlD
Propranolol—ABCB1—vagina—uterine cancer	0.000111	0.00885	CbGeAlD
Propranolol—Nausea—Doxorubicin—uterine cancer	0.000107	0.000677	CcSEcCtD
Propranolol—ABCB1—lymph node—uterine cancer	7.2e-05	0.00572	CbGeAlD
Propranolol—ADRB2—Signaling Pathways—FBXW7—uterine cancer	5.88e-06	0.000555	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	5.86e-06	0.000552	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—POLD1—uterine cancer	5.82e-06	0.000549	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—FBXW7—uterine cancer	5.75e-06	0.000542	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IGF1R—uterine cancer	5.74e-06	0.000542	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—CXCL8—uterine cancer	5.72e-06	0.000539	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	5.64e-06	0.000532	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—NRAS—uterine cancer	5.59e-06	0.000527	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AKR1C1—uterine cancer	5.58e-06	0.000526	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CYP11A1—uterine cancer	5.56e-06	0.000524	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—AKR1C3—uterine cancer	5.56e-06	0.000524	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—POLD1—uterine cancer	5.49e-06	0.000518	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AKR1C1—uterine cancer	5.45e-06	0.000514	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—SMAD3—uterine cancer	5.4e-06	0.000509	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—STK11—uterine cancer	5.25e-06	0.000496	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—AKR1C3—uterine cancer	5.25e-06	0.000495	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CCL2—uterine cancer	5.23e-06	0.000493	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CCL2—uterine cancer	5.21e-06	0.000491	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—CXCL8—uterine cancer	5.19e-06	0.00049	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	5.18e-06	0.000489	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—FGFR2—uterine cancer	5.15e-06	0.000486	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—STK11—uterine cancer	5.14e-06	0.000485	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AKR1C1—uterine cancer	5.13e-06	0.000484	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CCL2—uterine cancer	5.12e-06	0.000483	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—STK11—uterine cancer	5.03e-06	0.000474	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	5.01e-06	0.000473	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CCL2—uterine cancer	5e-06	0.000472	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—RRM2—uterine cancer	4.97e-06	0.000469	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—SOCS3—uterine cancer	4.92e-06	0.000464	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—PIK3CA—uterine cancer	4.87e-06	0.000459	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—RRM2—uterine cancer	4.85e-06	0.000458	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—DCN—uterine cancer	4.83e-06	0.000455	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—SOCS3—uterine cancer	4.81e-06	0.000454	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—KRAS—uterine cancer	4.81e-06	0.000454	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—DCN—uterine cancer	4.71e-06	0.000445	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CDKN2B—uterine cancer	4.71e-06	0.000444	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—SOCS3—uterine cancer	4.71e-06	0.000444	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—POLD1—uterine cancer	4.65e-06	0.000438	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CDKN2B—uterine cancer	4.61e-06	0.000435	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—RRM2—uterine cancer	4.57e-06	0.000431	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IGF1R—uterine cancer	4.57e-06	0.000431	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKR1B1—uterine cancer	4.57e-06	0.000431	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—STAR—uterine cancer	4.57e-06	0.000431	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—CXCL8—uterine cancer	4.55e-06	0.000429	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CYP11A1—uterine cancer	4.55e-06	0.000429	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CDKN2B—uterine cancer	4.51e-06	0.000425	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—MTHFR—uterine cancer	4.5e-06	0.000424	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—MTHFR—uterine cancer	4.49e-06	0.000424	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IGF1R—uterine cancer	4.47e-06	0.000422	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—CXCL8—uterine cancer	4.45e-06	0.00042	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—DCN—uterine cancer	4.44e-06	0.000419	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CYP11A1—uterine cancer	4.44e-06	0.000419	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—PIK3CA—uterine cancer	4.42e-06	0.000417	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—ESR1—uterine cancer	4.41e-06	0.000416	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IGF1R—uterine cancer	4.38e-06	0.000413	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—CXCL8—uterine cancer	4.36e-06	0.000411	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AKR1C1—uterine cancer	4.35e-06	0.00041	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—ERBB2—uterine cancer	4.34e-06	0.000409	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—STK11—uterine cancer	4.33e-06	0.000408	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CYP19A1—uterine cancer	4.33e-06	0.000408	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—SMAD3—uterine cancer	4.3e-06	0.000406	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AKR1C3—uterine cancer	4.3e-06	0.000405	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	4.23e-06	0.000399	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—SMAD3—uterine cancer	4.21e-06	0.000397	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AKR1C3—uterine cancer	4.19e-06	0.000395	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP11A1—uterine cancer	4.18e-06	0.000395	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—NRAS—uterine cancer	4.17e-06	0.000393	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CXCL8—uterine cancer	4.14e-06	0.00039	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CXCL8—uterine cancer	4.12e-06	0.000388	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—SMAD3—uterine cancer	4.11e-06	0.000388	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—FGFR2—uterine cancer	4.1e-06	0.000387	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—STK11—uterine cancer	4.09e-06	0.000386	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CYP19A1—uterine cancer	4.09e-06	0.000386	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—HRAS—uterine cancer	4.09e-06	0.000386	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CXCL8—uterine cancer	4.04e-06	0.000382	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CDKN1B—uterine cancer	4.02e-06	0.000379	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—FGFR2—uterine cancer	4.01e-06	0.000378	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—AKT1—uterine cancer	3.98e-06	0.000375	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CXCL8—uterine cancer	3.96e-06	0.000373	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AKR1C3—uterine cancer	3.95e-06	0.000373	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—FGFR2—uterine cancer	3.92e-06	0.00037	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCL2—uterine cancer	3.88e-06	0.000366	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—RRM2—uterine cancer	3.88e-06	0.000366	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.84e-06	0.000362	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CTNNB1—uterine cancer	3.8e-06	0.000358	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—DCN—uterine cancer	3.76e-06	0.000355	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—PTEN—uterine cancer	3.7e-06	0.000349	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.66e-06	0.000345	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—PIK3CA—uterine cancer	3.63e-06	0.000342	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—AKT1—uterine cancer	3.61e-06	0.000341	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—POLD1—uterine cancer	3.59e-06	0.000338	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—KRAS—uterine cancer	3.59e-06	0.000338	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP11A1—uterine cancer	3.54e-06	0.000334	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—EP300—uterine cancer	3.53e-06	0.000333	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—ESR1—uterine cancer	3.51e-06	0.000331	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—ESR1—uterine cancer	3.43e-06	0.000324	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ESR1—uterine cancer	3.36e-06	0.000317	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKR1C1—uterine cancer	3.36e-06	0.000317	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AKR1C3—uterine cancer	3.35e-06	0.000316	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—STK11—uterine cancer	3.35e-06	0.000316	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CYP19A1—uterine cancer	3.35e-06	0.000316	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—VEGFA—uterine cancer	3.34e-06	0.000315	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—NRAS—uterine cancer	3.32e-06	0.000313	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—NRAS—uterine cancer	3.3e-06	0.000311	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—PIK3CA—uterine cancer	3.29e-06	0.000311	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CYP19A1—uterine cancer	3.27e-06	0.000308	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—STK11—uterine cancer	3.27e-06	0.000308	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—MTHFR—uterine cancer	3.25e-06	0.000307	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—NRAS—uterine cancer	3.25e-06	0.000306	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—ERBB2—uterine cancer	3.23e-06	0.000305	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—NRAS—uterine cancer	3.17e-06	0.000299	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.14e-06	0.000296	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCL2—uterine cancer	3.09e-06	0.000291	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—STK11—uterine cancer	3.08e-06	0.00029	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP19A1—uterine cancer	3.08e-06	0.00029	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—MTHFR—uterine cancer	3.07e-06	0.00029	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CXCL8—uterine cancer	3.07e-06	0.000289	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—HRAS—uterine cancer	3.05e-06	0.000287	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCL2—uterine cancer	3.02e-06	0.000285	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3e-06	0.000283	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CDKN1B—uterine cancer	3e-06	0.000283	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—RRM2—uterine cancer	2.99e-06	0.000282	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—AKT1—uterine cancer	2.96e-06	0.000279	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCL2—uterine cancer	2.96e-06	0.000279	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—DCN—uterine cancer	2.9e-06	0.000274	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—PIK3CA—uterine cancer	2.89e-06	0.000272	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—KRAS—uterine cancer	2.86e-06	0.000269	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—KRAS—uterine cancer	2.84e-06	0.000268	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CTNNB1—uterine cancer	2.83e-06	0.000267	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—PIK3CA—uterine cancer	2.83e-06	0.000267	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—KRAS—uterine cancer	2.79e-06	0.000263	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—PIK3CA—uterine cancer	2.76e-06	0.000261	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PTEN—uterine cancer	2.76e-06	0.00026	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.74e-06	0.000258	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—KRAS—uterine cancer	2.73e-06	0.000258	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.71e-06	0.000255	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—AKT1—uterine cancer	2.69e-06	0.000254	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—EP300—uterine cancer	2.63e-06	0.000248	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—PIK3CA—uterine cancer	2.62e-06	0.000247	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—PIK3CA—uterine cancer	2.61e-06	0.000246	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—STK11—uterine cancer	2.61e-06	0.000246	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP19A1—uterine cancer	2.61e-06	0.000246	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.58e-06	0.000244	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—ERBB2—uterine cancer	2.58e-06	0.000243	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—PIK3CA—uterine cancer	2.57e-06	0.000242	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TP53—uterine cancer	2.53e-06	0.000238	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—ERBB2—uterine cancer	2.52e-06	0.000238	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—MTHFR—uterine cancer	2.51e-06	0.000237	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—PIK3CA—uterine cancer	2.51e-06	0.000237	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTEN—uterine cancer	2.5e-06	0.000236	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTEN—uterine cancer	2.5e-06	0.000236	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—VEGFA—uterine cancer	2.49e-06	0.000235	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ERBB2—uterine cancer	2.46e-06	0.000232	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NRAS—uterine cancer	2.46e-06	0.000232	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—MTHFR—uterine cancer	2.45e-06	0.000232	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.45e-06	0.000231	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CXCL8—uterine cancer	2.44e-06	0.00023	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—HRAS—uterine cancer	2.43e-06	0.000229	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—HRAS—uterine cancer	2.42e-06	0.000228	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CXCL8—uterine cancer	2.39e-06	0.000225	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—EP300—uterine cancer	2.39e-06	0.000225	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CDKN1B—uterine cancer	2.39e-06	0.000225	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—EP300—uterine cancer	2.38e-06	0.000225	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—HRAS—uterine cancer	2.37e-06	0.000224	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—AKT1—uterine cancer	2.36e-06	0.000223	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CXCL8—uterine cancer	2.34e-06	0.00022	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.33e-06	0.00022	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CDKN1B—uterine cancer	2.33e-06	0.00022	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—HRAS—uterine cancer	2.32e-06	0.000219	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—MTHFR—uterine cancer	2.31e-06	0.000218	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—AKT1—uterine cancer	2.31e-06	0.000218	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CDKN1B—uterine cancer	2.28e-06	0.000215	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—AKT1—uterine cancer	2.26e-06	0.000213	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CTNNB1—uterine cancer	2.25e-06	0.000213	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.22e-06	0.000209	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CTNNB1—uterine cancer	2.2e-06	0.000208	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PTEN—uterine cancer	2.2e-06	0.000207	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CTNNB1—uterine cancer	2.16e-06	0.000203	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PTEN—uterine cancer	2.15e-06	0.000203	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—AKT1—uterine cancer	2.14e-06	0.000202	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—AKT1—uterine cancer	2.13e-06	0.000201	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—KRAS—uterine cancer	2.12e-06	0.0002	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PTEN—uterine cancer	2.1e-06	0.000198	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—AKT1—uterine cancer	2.1e-06	0.000198	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—EP300—uterine cancer	2.09e-06	0.000198	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—AKT1—uterine cancer	2.05e-06	0.000193	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—EP300—uterine cancer	2.05e-06	0.000193	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—STK11—uterine cancer	2.01e-06	0.00019	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP19A1—uterine cancer	2.01e-06	0.00019	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—EP300—uterine cancer	2e-06	0.000189	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—VEGFA—uterine cancer	1.98e-06	0.000187	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NRAS—uterine cancer	1.96e-06	0.000185	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—MTHFR—uterine cancer	1.96e-06	0.000185	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PIK3CA—uterine cancer	1.95e-06	0.000184	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—VEGFA—uterine cancer	1.94e-06	0.000183	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NRAS—uterine cancer	1.92e-06	0.000181	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—VEGFA—uterine cancer	1.9e-06	0.000179	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TP53—uterine cancer	1.88e-06	0.000178	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NRAS—uterine cancer	1.87e-06	0.000177	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTEN—uterine cancer	1.81e-06	0.000171	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—HRAS—uterine cancer	1.8e-06	0.00017	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CA—uterine cancer	1.77e-06	0.000167	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CA—uterine cancer	1.76e-06	0.000166	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.73e-06	0.000163	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—EP300—uterine cancer	1.73e-06	0.000163	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTEN—uterine cancer	1.71e-06	0.000161	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KRAS—uterine cancer	1.69e-06	0.000159	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KRAS—uterine cancer	1.65e-06	0.000156	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—EP300—uterine cancer	1.63e-06	0.000154	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KRAS—uterine cancer	1.61e-06	0.000152	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—AKT1—uterine cancer	1.59e-06	0.00015	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CA—uterine cancer	1.55e-06	0.000146	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CA—uterine cancer	1.52e-06	0.000143	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—MTHFR—uterine cancer	1.51e-06	0.000143	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TP53—uterine cancer	1.5e-06	0.000141	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CA—uterine cancer	1.48e-06	0.00014	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TP53—uterine cancer	1.47e-06	0.000138	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—AKT1—uterine cancer	1.44e-06	0.000136	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—AKT1—uterine cancer	1.44e-06	0.000136	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TP53—uterine cancer	1.43e-06	0.000135	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—HRAS—uterine cancer	1.43e-06	0.000135	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—HRAS—uterine cancer	1.4e-06	0.000132	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTEN—uterine cancer	1.4e-06	0.000132	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—HRAS—uterine cancer	1.37e-06	0.000129	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTEN—uterine cancer	1.37e-06	0.000129	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—EP300—uterine cancer	1.33e-06	0.000126	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—EP300—uterine cancer	1.3e-06	0.000123	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTEN—uterine cancer	1.29e-06	0.000121	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CA—uterine cancer	1.28e-06	0.00012	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—AKT1—uterine cancer	1.27e-06	0.000119	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—AKT1—uterine cancer	1.24e-06	0.000117	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—EP300—uterine cancer	1.23e-06	0.000116	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—AKT1—uterine cancer	1.21e-06	0.000114	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CA—uterine cancer	1.21e-06	0.000114	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTEN—uterine cancer	1.09e-06	0.000103	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—AKT1—uterine cancer	1.04e-06	9.84e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—EP300—uterine cancer	1.04e-06	9.81e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CA—uterine cancer	9.87e-07	9.31e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—AKT1—uterine cancer	9.85e-07	9.29e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CA—uterine cancer	9.63e-07	9.09e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CA—uterine cancer	9.08e-07	8.56e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTEN—uterine cancer	8.41e-07	7.94e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AKT1—uterine cancer	8.06e-07	7.61e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—EP300—uterine cancer	8.02e-07	7.57e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AKT1—uterine cancer	7.87e-07	7.42e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CA—uterine cancer	7.69e-07	7.25e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AKT1—uterine cancer	7.42e-07	7e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AKT1—uterine cancer	6.28e-07	5.93e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CA—uterine cancer	5.94e-07	5.6e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKT1—uterine cancer	4.85e-07	4.57e-05	CbGpPWpGaD
